| Name | PHI-101 |
|---|---|
| Synonyms |
2-Thiophenecboxamide, 3-[(aminocbonyl)amino]-5-[2-(3-fluorophenyl)ethynyl]-N-(3S)-3-piperidinyl
(S)-5-((3-Fluorophenyl)ethynyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-cboxamide |
| Description | PHI-101 is an orally active FLT3 inhibitor that overcomes resistance to multiple drug-resistant mutations. PHI-101 potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. PHI-101 has potential for research in relapsed or refractory acute myeloid leukemia (AML)[1]. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C19H19FN4O2S |
|---|---|
| Molecular Weight | 386.44 |